| Literature DB >> 30802315 |
Jaideep Sandhu1, Viraj Lavingia2, Marwan Fakih3.
Abstract
The treatment of metastatic colorectal cancer has evolved over the last two decades with the FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review the impact of sidedness, RAS, BRAF, HER-2, and other immune biomarkers on metastatic colorectal cancer treatment selection and sequencing in both the palliative and curative intent settings.Entities:
Keywords: biomarkers; chemotherapy; colorectal cancer; immunotherapy; targeted therapy
Mesh:
Substances:
Year: 2019 PMID: 30802315 DOI: 10.1002/jso.25421
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 3.454